Actively Recruiting
Testing the Safety and Effectiveness of Adding Imatinib to Artemether-Lumefantrine for Treating Uncomplicated Malaria in Children and Adults
Led by Victoria Biomedical Research Institute · Updated on 2026-06-29
1116
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new approach to treat uncomplicated malaria by adding a drug called Imatinib to the current standard treatment of Artemether and Lumefantrine AL. The goal is to clear infections faster and prevent the spread of drug-resistant malaria parasites, which is a significant problem in Africa. Imatinib works differently by targeting a human enzyme that the parasite uses to escape red blood cells, making it harder for the parasite to develop resistance. The study involves several phases. Initially, adults will receive varying doses of Imatinib combined with AL to find the safest dose. Then, a larger group of adults will test the safety and effectiveness of this combination, comparing a two-day versus the usual three-day course. Finally, the trial will include children aged 12 months to 17 years, using doses based on their weight. Participants stay in the hospital for 48 to 72 hours for close monitoring during treatment. During the study, participants will have frequent blood tests to measure parasite levels and monitor liver and kidney health. Follow-up visits occur on days 7, 21, and 35 to check if the infection returns. The study covers all medical and travel expenses and provides compensation for time lost. Safety is closely monitored by an independent board, and personal data is protected under Kenyan law.
CONDITIONS
Brief Title
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Research Team
D
Dr. Quentin Awori, MBChB
D
David Owino Ogolla, Msc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here